Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
BCL2L11	10018	IMATINIB	CHEMBL941		CIViC	22426421
BCL2L11	10018	CHEMBL387187	CHEMBL387187		CIViC	22426421

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
BCL2L11	rs724710	T	imatinib	efficacy	yes	The T allele was also significantly associated with presence of mutations in the kinase domain of the BCR-ABL fusion protein and resistance to tyrosine kinase inhibitors. Response was defined as a ratio of BCR-ABl/ABl of less than or equal to 0.1% by 18 months of treatment with imatinib.	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.	24223824	1184821109